worldwide offices | contact | site map | large text versionregular text version

Novartis Pharmaceuticals Corporation - A site intended for US audiences

 

 

 

Newsroom

Press Releases

Latest Novartis Pharmaceuticals Press Releases

Novartis press releases are listed below by date. To read a release, click on its title, or, to access older releases, just scroll down the list.

15-Apr-2008
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

15-Apr-2008
Patients with early Parkinson's disease show better symptom control and improvements in daily activities with Stalevo than carbidopa/levodopa

11-Apr-2008
Study shows once-yearly Reclast better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids

31-Mar-2008
Novartis and FDA complete Two-year Cooperative Research and Development Agreement (CRADA) To Define and Test a Process for Qualifying Preclinical Safety Biomarkers

31-Mar-2008
Lotrel, a single-pill combination for treating high blood pressure, reduced cardiovascular events by 20% in high-risk patients

27-Mar-2008
Head-to-head study suggests Focalin® XR provides superior symptom management in the early part of the ADHD patient's day compared to Concerta®

21-Jan-2008
Tekturna HCT®, a single-tablet combination of Tekturna® and a diuretic, receives US approval for treatment of high blood pressure

20-Dec-2007
New Study Reports Two Thirds of Renal Recipients Switched to myfortic® Experience an Improvement in Gastrointestinal Symptom Burden

3-Dec-2007
FDA approves Diovan® for treatment of high blood pressure in children

12-Nov-2007
Novartis and Orion Submit Application to U.S. Food and Drug Administration for Approval of a New Product for Parkinson's Disease

2-Nov-2007
FDA Approves Supplemental New Drug Application for Antiviral Treatment Famvir®

12-Oct-2007
New preclinical data suggests FTY720 may repair or reduce damage caused by Multiple Sclerosis through a direct effect in the brain

17-Sep-2007
First osteoporosis study in hip fracture patients finds once-yearly Reclast® prevents additional fractures and improves survival

17-Aug-2007
Reclast® receives US FDA approval as first and only once-yearly treatment for women with postmenopausal osteoporosis

10-Aug-2007
FDA grants additional six months marketing exclusivity for the high blood pressure medicine Diovan®

3-Aug-2007
New dosage strength of Stalevo® approved in US provides additional dosing flexibility for people with Parkinson's disease

27-Jul-2007
Zelnorm® to be made available to US patients under restricted access program

9-Jul-2007
Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US

21-Jun-2007
Exforge® receives final US approval as new and powerful treatment option for patients with high blood pressure

21-May-2007
High Blood Pressure Patients Starting on Higher Doses of Diovan® or Diovan HCT® Achieve Control Quicker Than Patients Starting on Lower Doses Despite Titration in Non-Responders

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

WHO WE ARE

We are a world leader in healthcare, with core businesses in pharmaceuticals, consumer health, generics, eye care, and animal health.

PRODUCTS

We strive to provide a broad range of innovative therapies and practical solutions.

INVESTORS

Investors

Find general financial information, company news, annual reports and financial statements.